DaVita and HealthCare Partners Announce Merger Agreement
DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), and HealthCare Partners, the country’s largest operator of medical groups and physician networks, announced today that they have entered into a definitive merger agreement. The two companies expect to close the transaction early in the fourth quarter of this year. Upon closing, the combined company will be named DaVita HealthCare Partners Inc. The purchase price to be p...continuedDVA Healthcare kidney dialysis
Related News:
- DaVita Inc. Schedules 1st Quarter 2012 Investor Conference Call
- DaVita Inc. Schedules 4th Quarter 2011 Investor Conference Call
- DaVita 1st Quarter 2012 Results
- Summit Housing Partners, LLC and Bailey Properties, LLC Announce Merger to Create BSR Trust
- Green Automotive Signs Merger Agreement With Matter of Time I Inc.
- Water Street and Wind Point Partners Announce Agreement to Sell Physiotherapy Associates to Court Square Capital Partners
- Cordillera Energy Partners III, LLC Completes Merger With Apache Corporation
Dynacq Healthcare Announces the Death of Chiu M. Chan, Founder and Chairman of the Board
We are deeply saddened to announce that Chiu M. Chan, the Chairman and founder of Dynacq Healthcare, Inc. (NASDAQ:DYII), passed away yesterday morning. He had been incapacitated by an unexpected illness since January of this year. He was 59. Our hearts go out to his wife, Ella, his children and his family during this tragic time. Chiu’s passion, dedication and energy left an indelible mark on Dynacq and the healthcare industry. Eric K. Chan, Chiu’s son and our CEO, President ...continuedDYII Healthcare medicare dynacq
Related News:
- H&Q Healthcare Investors and H&Q Life Sciences Investors Announce Death of Chairman Lawrence Lewin
- TriZetto Founder Jeff Margolis Sets Sights on Fusing Healthcare Population Management and Social Networking Technology
- Professor K.C. Chan, Secretary for Financial Services and the Treasury, Invites New York’s Financiers to Sample the Benefits of Doing Business in Hong Kong
- QuickMobile Names PhoCusWright Founder Philip C. Wolf as Chairman of the Board
- Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year 2012 Award in New Jersey
- Greatbatch, Inc. to Participate in the 2012 RBC Capital Markets’ Healthcare Conference
- Santa Fe Gold Announces Death of Chairman Lawrence Olson
Kindred Healthcare Announces Voting Results for the 2012 Annual Meeting of Shareholders
Kindred Healthcare, Inc. (the “Company”) (NYSE: KND) today announced the voting results of the Company’s 2012 Annual Meeting of Shareholders held on May 17, 2012. At the annual meeting, the Company’s shareholders voted to elect the following board members to terms expiring at the Company’s 2013 Annual Meeting of Shareholders: Edward L. Kuntz, Joel Ackerman, Jonathan D. Blum, Dr. Thomas P. Cooper, Paul J. Diaz, Christopher T. Hjelm, Isaac Kaufman, Frederick J. Kle...continuedKND kindred nursing Healthcare
Related News:
- Automated Benefits Corp. Announces Voting Results of the Special Meeting of Shareholders and New Chief Financial Officer
- Canadian Pacific announces results of 2012 annual meeting of shareholders
- Canadian Pacific announces results of 2012 annual meeting of shareholders
- KWG Announces Annual and General Meeting of Shareholders
- Spectrum Brands Holdings Announces Voting Results for Proposals at 2012 Annual Meeting of Stockholders
- Canexus to Hold Annual General Meeting of Shareholders and 2012 First Quarter Results Conference Call
- Kindred Healthcare to Present at the J.P. Morgan Healthcare Conference
Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
RAPID AND SIGNIFICANT REDUCTION IN URIC ACID OBSERVED IN ALL SUBJECTS ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion ...continuedPARS pharmaceutical pharma Healthcare
Related News:
- Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
- Pharmos Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
- Pharmos Corporation Reports First Quarter 2012 Results
- Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
- Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer
- Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
- Further Analysis Reveals Double Digit Hair Growth in RepliCel’s First-in-man Clinical Trial
A.M. Best Affirms Ratings of Coventry Health Care, Inc. and Upgrades Ratings of Selected Subsidiaries
A.M. Best Co. has affirmed the issuer credit rating (ICR) of “bbb-” and all debt ratings of Coventry Health Care, Inc. (Coventry) (Delaware) (NYSE: CVH). At the same time, A.M. Best has upgraded the financial strength rating (FSR) to A- (Excellent) from B++ (Good) and the ICRs to “a-” from “bbb+” for Coventry Health Care of Iowa, Inc. (Omaha, NE) and Coventry Health Care of Illinois, Inc. (Champaign, IL) (f/k/a PersonalCare Insurance of Illinois, I...continuedCVH Healthcare ppo coventry
Related News:
- Coventry Health Care Reports Fourth Quarter Earnings
- A.M. Best Upgrades Ratings of Central States Health & Life Co. of Omaha and Its Two Subsidiaries
- A.M. Best Upgrades Issuer Credit Rating of UPMC Health Plan, Inc. and Its Affiliates; Revises Outlook to Positive
- A.M. Best Upgrades Issuer Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries
- A.M. Best Upgrades Issuer Credit Ratings of SCOR SE and Its Main Subsidiaries
- A.M. Best Upgrades Ratings of Partners Mutual Insurance Company and Affirms Ratings of Penn National Insurance and Its Members
- Fitch Affirms Resurrection Health Care’s (IL) Revs at ‘BBB+’; Outlook Stable
Invacare Declares Quarterly Dividend
The Board of Directors of Invacare Corporation (NYSE:IVC) announced that it declared a cash dividend of $.0125 per share on its common shares and $.011364 per share on its Class B common shares payable July 13, 2012 to shareholders of record on July 5, 2012. Invacare Corporation (NYSE:IVC - news), headquartered in Elyria, Ohio, is the global leader in the manufacture and distribution of innovative home and long-term care medical products that promote recovery and active lifestyles. The Company has...continuedIVC Healthcare rollator scooters
Related News:
- Terreno Realty Corporation Declares Quarterly Dividend
- Westway Group, Inc. Declares Quarterly Dividend
- Brady Corporation Declares Quarterly Dividend to Shareholders
- First American Financial Corporation Declares Quarterly Cash Dividend Of Eight Cents Per Share
- Regis Declares Regular Quarterly Dividend
- UIL Holdings Corporation Declares Quarterly Dividend
- Union Pacific Corporation Declares Quarterly Dividend
Human Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that its Board of Directors, after careful review and consideration with the assistance of the Company’s management and financial and legal advisors, has unanimously determined that the unsolicited tender offer from GlaxoSmithKline (“GSK”) to acquire all outstanding common shares of HGS for $13.00 per share in cash (the “Offer”) is inadequate, undervalues the Company and is not in the best interests of HGS an...continuedHGSI Healthcare biotechnology hgsi
Related News:
- Illumina’s Board of Directors to Review Unsolicited Tender Offer from Roche
- Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2012 Financial Results
- Icahn Updates Information Regarding Tender Offer To Acquire CVR Energy
- CVR Energy Advises Shareholders to Take No Action Regarding Unsolicited Takeover Offer from Carl Icahn Pending Board Review
- Icahn Comments on CVR Energy Tender Offer
- FBR & Co. Commences Self Tender Offer to Purchase up to Four Million Shares
- TKH Announces Commencement of Tender Offer for Outstanding Shares of Augusta Technologie Aktiengesellschaft
Quality Systems, Inc. Reports Fiscal 2012 Fourth Quarter and Year-End Results
Quality Systems, Inc. (NASDAQ:QSII) announced today results for its fiscal year and fourth quarter ended March 31, 2012. The Company reported revenues of $429.8 million for the fiscal year ended March 31, 2012, an increase of 22 percent compared to $353.4 million for the fiscal year ended March 31, 2011. Net income for fiscal 2012 was $75.7 million, a 23 percent increase versus net income of $61.6 million for the year ago period. Fully diluted earnings per share for the fiscal year ended 2012 was ...continuedQSII Healthcare security conference
Related News:
- Quality Systems, Inc. to Host Fiscal 2012 Third Quarter Results Conference Call
- Quality Systems, Inc. Chief Financial Officer Named 2012 CFO of the Year by Orange County Business Journal
- National Technical Systems Reports Fiscal 2012 Fourth Quarter, Year-End Results
- Honda Motor Co., Ltd. Reports Consolidated Financial Results For The Fiscal Fourth Quarter And The Fiscal Year Ended March 31, 2012
- Triumph Group Reports Record Fourth Quarter and Full Fiscal Year 2012 Results
- Nortech Systems Reports Fourth Quarter, Fiscal 2011 Year-End Results
- NexJ Systems Reports Fourth Quarter and Full Year 2011 Results
Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington’s and Parkinson’s Diseases
Company Files Three Patent Applications for Methods of Diagnosis and Treatment of Neurodegenerative Diseases Based on Production of Antibodies, and Vaccines that Selectively Target the Earliest Forms of Neurotoxic Proteins. NEW YORK, May 16, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced ...continuedILNS Healthcare neuroscience memory
Related News:
- Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer’s disease
- Intellect Neurosciences Adds Two New Tau Programs to its Alzheimer’s Disease Development Pipeline
- Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN( Alzheimer’s Disease Immunotherapy Technology Platform
- Intellect Neurosciences Issues Letter to Shareholders
- Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
- Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA( for the Acute Treatment of Migraine
- Research and Markets: Orphan Diseases Therapeutics in CNS to 2017 – Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
Cyberonics To Report Fourth Quarter And Fiscal Year 2012 Results And Host Conference Call On June 6, 2012
HOUSTON, May 16, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the company will report financial results for the fourth quarter and fiscal year ended April 27, 2012, on Wednesday, June 6, 2012, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fourth Quarter and Fiscal Year 2012 Results Conference Call Instructions The conference call will ...continuedCYBX Financial Healthcare cyberonics
Related News:
- Cyberonics to Report Fiscal Year 2012 Third Quarter Results and Host Conference Call on February 24, 2012
- Smithfield Foods to Host Fiscal 2012 Fourth Quarter Conference Call June 14
- Cyberonics Reports Record Fiscal 2012 Third Quarter Results
- Entertainment Gaming Asia to Report Fourth Quarter and 2011 Fiscal Year Results on March 8, 2012 and Host Conference Call and Webcast
- GT Advanced Technologies To Host Fourth Quarter and Fiscal Year 2012 Conference Call and Webcast on May 17th
- Booz Allen Hamilton to Host Conference Call to Discuss Fourth Quarter and Full-Year Fiscal 2012 Results on Wednesday, May 30, 2012
- Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2011 Financial Results and Host Conference Call on March 14, 2012
Angeion Corporation to Report Second Quarter Fiscal 2012 Financial Results on Thursday, May 31, 2012
SAINT PAUL, Minn., May 16, 2012 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today scheduled a conference call to discuss its financial results for the second quarter fiscal 2012, ended April 30, 2012. The call will be at 11:00 a.m. ET on Thursday, May 31, 2012. The Company will report financial results for the second quarter fiscal 2012 before market opens on Thursday, May 31, 2012. Those wishing to participate can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or liste...continuedANGN Medical Healthcare Financial
Related News:
- Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
- Chyron Corporation to Report Financial Results for the First Quarter of Fiscal Year 2012 on Thursday, May 3, 2012
- Chyron Corporation to Report Financial Results for the Fourth Quarter and Fiscal Year 2011 on Thursday, March 8, 2012
- Abaxis to Report Third Quarter Fiscal Year 2012 Financial Results Thursday, January 26, 2012
- Unilife Corporation to Announce Financial Results for Fiscal 2012 Second Quarter on Thursday, February 9, 2012
- Abaxis to Report Third Quarter Fiscal Year 2012 Financial Results Thursday, January 26, 2012
- Heckmann Corporation to Report 2012 First Quarter Financial Results on Thursday, May 3
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results
WEIFANG, China, May 16, 2012 /PRNewswire-Asia/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "we" or "us"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the third quarter of fiscal 2012 ended March 31, 2012. Third Quarter Fiscal Year 2012 Result of Operations Net sales for the three months ended March 31, 2012 were $3...continuedSGTI Healthcare Drugs
Related News:
- Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results
- Shengtai Pharmaceutical, Inc. Establishes Special Committee to Evaluate Non-binding Going Private Proposal
- Pomerantz Law Firm Investigates Claims on Behalf of Investors of Shengtai Pharmaceutical, Inc.
- Rigrodsky & Long, P.A. Announces Investigation Of Shengtai Pharmaceutical, Inc. Going Private Proposal
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Shengtai Pharmaceutical, Inc. in Connection with the Receipt of a Going Private Proposal
- Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
- China Pharma Holdings, Inc. to Report Fiscal Year 2011 Financial Results on March 15, 2012
Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood...continuedSTJ Healthcare heart electrophysiology
Related News:
- Trial of Medtronic Symplicity(tm) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
- St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
- Medtronic Symplicity(tm) Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction out to Three Years
- ReCor Medical Announces CE Mark Approval for Its Novel PARADISE(tm) Ultrasound Transcatheter Renal Denervation System
- Vessix to Present V2 Renal Denervation System(tm) for Hypertension at LINC 2012
- Vessix to Present V2 Renal Denervation System(tm) for Hypertension at LINC 2012
- Sound Interventions Completes "First-In-Human" Feasibility Trial of Ultrasound-Based Renal Denervation System For Resistant Hypertension
Akela Pharma reports financial results for the three months ended March 31, 2012
AUSTIN, TX, May 15, 2012 /CNW Telbec/ - Akela Pharma, Inc. ("Akela"), (TSX: AKL), an industry leader in providing pharmaceutical contract dosage development and clinical and commercial manufacturing, today announced its financial results for the three months ended March 31, 2012. Total consolidated revenues for the three months ended March 31, 2012 were $0.8 million in contract services, as compared to $4.2 million, including $3.5 million of contract services, for 2011. Consolidated net loss ...continuedAKL:CA Drugs Healthcare
Related News:
- Akela Pharma reports financial results for the year ended 2011
- Akela Pharma reports financial results for the year ended 2011
- Innovaro, Inc. Reports Financial Results for Three Months Ended March 31, 2012
- Daily Journal Corporation Announces Financial Results for the Six Months ended March 31, 2012
- Sonor Investments Limited Reports Financial Results for the Year Ended December 31, 2011 and Three Months Ended March 31, 2012
- Badger Daylighting Ltd. Announces Results for the Three Months Ended March 31, 2012
- Patterson-UTI Energy Reports Financial Results for Three Months Ended March 31, 2012
Silvermex Resources Announces Q1 2012 Financial Results
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 15, 2012) - Silvermex Resources Inc. ("Silvermex") (TSX:SLX) reported today its unaudited financial results for the quarter ended March 31, 2012. Highlights from the quarter, which should be read in conjunction with the unaudited financial statement and management's discussion and analysis available at www.silvermexresources.com and www.sedar.com, include: The Company entered into a definitive agreement with First Majestic Silver Corp. ("First M...continuedSLX:CA Drugs Healthcare
Related News:
- First Majestic Announces Friendly Acquisition of Silvermex Resources
- Silvermex Aims to Deliver Resource and Production Growth in 2012
- Silvermex Reports Positive Financial Performance for the Year 2011
- Silvermex Reports Positive Financial Performance for the Year 2011
- Silvermex Files Form 40-F Registration Statement With the SEC
- Silvermex Intersects High Grade Gold at La Guitarra-306.99 g/t Au and 1,033.60 g/t Ag or 18,225 g/t Silver Equivalent Over 1.45 Meters
- Maxim Power Corp. Announces 2012 First Quarter Financial and Operating Results
Nile Therapeutics Reports 2012 First Quarter Financial Results
SAN FRANCISCO, May 15, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012. For the first quarter of 2012, Nile reported a net operating loss of $0.8 million, or $0.02 per share. Weighted-average shares outstanding for the quarter were 39.7 million. Nile reported collaboration income of $0.2 million during the quarter ended March...continuedNLTX Drugs Healthcare
Related News:
- Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
- Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
- Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
- Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
- Blue Nile Announces Fourth Quarter and Fiscal Year 2011 Financial Results
- Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
- United Therapeutics Corporation Reports First Quarter 2012 Financial Results
Cambridge Heart Reports Results for the Three Months Ended March 31, 2012
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its first quarter ended March 31, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on May 15, 2012. Cambridge Heart addresses a key problem in cardiac diagnosis – the identification of those at risk of sudden cardiac death. Sudden cardiac arrest ...continuedCAMH reimbursement heart Healthcare
Related News:
- Cambridge Heart Reports Results for the Three and Twelve Months Ended December 31, 2011
- AMERICAN IDOL LIVE! Partners With The Heart Foundation One For The Heart Campaign By Donating $1 Of Each AMERICAN IDOL LIVE! TOUR 2012 Ticket Sold To Support Heart Disease Research
- This February The New York Palace Introduces New ‘Have a Heart’ Program, Inviting Visitors to Take Care of the Heart They Love
- Community Investors Bancorp, Inc. Reports Net Earnings For The Nine Months and Three Months Ended March 31, 2012
- Cedars-Sinai Implants 1st SynCardia Total Artificial Heart to Bridge Mother of Three to Second Heart Transplant
- Sonor Investments Limited Reports Financial Results for the Year Ended December 31, 2011 and Three Months Ended March 31, 2012
- MDC Partners Inc. Reports Results For The Three Months Ended March 31, 2012
Spherix Announces First Quarter 2012 Financial Results
BETHESDA, Md., May 15, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the three months ended March 31, 2012, and recent and upcoming business highlights. First Quarter and Upcoming Highlights Pharmaceutical...continuedSPEX Healthcare domain
Related News:
- Spherix Announces 2011 Financial Results
- Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2012 Financial Results
- PDL BioPharma to Announce First Quarter 2012 Financial Results on May 3, 2012
- Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2011 Financial Results on February 16, 2012
- Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
BELLUS Health Securityholders Vote in Favour Of $17.25 Million Strategic Transaction with Pharmascience
- BELLUS Health reports results for the first quarter ended March 31, 2012, and provides corporate update - LAVAL, QC, May 15, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today conducted its Annual and Special Meeting of Securityholders in relation to the $17.25 million strategic transaction and financing with Pharmascience Inc. ("Pharmascience") announced on April 5, 2012. The Company also reported its financial results for the first quarter ended Marc...continuedBLU:CA BLUS Drugs Drugs Healthcare
Related News:
- Health Care REIT, Inc. Announces $508 Million of First Quarter 2012 Acquisitions
- Fitch Rates Memorial Health Services (CA) Series 2012A Bonds ‘AA-’; Outlook Stable
- Shareholders of iPerceptions Vote in Favour of the Amalgamation With XPND
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Catalyst Health Solutions Inc. in Connection with the Sale of the Company to SXC Health Solutions, Corp.
- The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Catalyst Health Solutions Inc. in Connection with the Sale of the Company to SXC Health Solutions, Corp.
- Health Net Reports Fourth Quarter 2011 GAAP Net Income of $60.2 Million, or $0.71 Per Diluted Share
- Metropolitan Health Networks Reports 2011 Results of Operations
ABMC Reports First Quarter 2012 Results
American Bio Medica Corporation (ABMC.PK) today announced financial results for the three months ended March 31, 2012. Net sales for the first quarter of 2012 were $2,296,000, an increase of $249,000, or 12.2%, when compared to net sales of $2,047,000 for the first quarter of 2011. Operating loss for the first quarter of 2012 was $169,000, compared to an operating loss of $374,000 in the first quarter of 2011. Net loss for the first quarter of 2012 was $206,000, or $0.01 per share, compared to a n...continuedABMC Healthcare Drugs usb
Related News:
- ABMC Reports Fourth Quarter and Year End 2011 Results
- Furniture Brands International Reports First Quarter 2012 Financial Results
- Katy Industries, Inc. Reports 2012 First Quarter Results
- Tembec reports financial results for its first quarter ended December 24, 2011
- Phoenix Footwear Reports First Quarter 2012 and 2011 Year End Results
- Alterra Capital Reports First Quarter 2012 Results
- Capitol Bancorp Reports First Quarter Results
Nymox Reports First Quarter 2012 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2012. Nymox reported a net loss of $1,846,974, or $0.06 per share for the quarter ended March 31, 2012, compared to $4,431,091, or $0.14 per share for the quarter ended March 31, 2011. Net losses include stock-based compensation charges of $51,496 in the quarter ended March 31, 2012 and $3,583,258 in the comparative period in 2011. The ...continuedNYMX dementia Healthcare Drugs
Related News:
- Nymox Reports 2011 Financial Results
- Critical Outcome Technologies Inc. Reports Fiscal 2012 Third Quarter Financial Results
- Green Plains Reports First Quarter 2012 Financial Results
- Isotechnika Reports First Quarter 2012 Financial Results
- Comstock Resources, Inc. Reports First Quarter 2012 Financial and Operating Results
- Palomar Medical Reports Financial Results for First Quarter 2012
- First Savings Financial Group, Inc. Reports 2012 Second Quarter Financial Results
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Drs. Kathy D. Miller and Hope S. Rugo join SAB WORCESTER, Mass. and TORONTO, May 15, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation of the transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatment...continuedGNBT GNTB biotechnology pharmaceutical Healthcare
Related News:
- Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
- Generex Announces Establishment of a Scientific Advisory Board for Antigen Express
- Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company’s Scientific Advisory Board
- Computer Vision Systems Laboratories Corp. Announces the Appointment of Dr. David Fiorella to Its Scientific Advisory Board
- AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
- Los Angeles Syndicate of Technology Announces its Portfolio Company, Sanguine BioSciences, Inc. Makes Major Appointment to Scientific Advisory Board
- PRVCY Appoints Robert DeSantis Chairman of the Advisory Board
St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of the company’s renal denervation technology wi...continuedSTJ tachycardia electrophysiology Healthcare
Related News:
- Trial of Medtronic Symplicity(tm) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
- ReCor Medical Announces CE Mark Approval for Its Novel PARADISE(tm) Ultrasound Transcatheter Renal Denervation System
- Vessix to Present V2 Renal Denervation System(tm) for Hypertension at LINC 2012
- Medtronic Symplicity(tm) Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction out to Three Years
- Sound Interventions Completes "First-In-Human" Feasibility Trial of Ultrasound-Based Renal Denervation System For Resistant Hypertension
- Vessix to Present V2 Renal Denervation System(tm) for Hypertension at LINC 2012
- Groundbreaking Treatment Cures Hypertension, Atherosclerosis and High Cholesterol
IDC Reports First Quarter 2012 Results
CALGARY, May 14, 2012 /CNW/ - Imaging Dynamics Company Ltd. ("IDC" or the "Company") (TSX: IDL) a global leader in the high growth digital radiography (DR) equipment market, today reported financial results for the first quarter end March 31, 2012. First quarter 2012 Highlights Gross revenues were lower by 46 percent to $1.1 million compared to $2.0 million for the same quarter last year mainly due to decrease in revenues from Asia Pacific and Latin America regions; Gross margins remai...continuedIDL:CA Healthcare
Related News:
- IDC Reports Fourth Quarter and Year End 2011 Results
- USEC Reports First Quarter 2012 Results
- Hollysys Automation Technologies Reports Unaudited Financial Results for the Fiscal Year 2012 Second Quarter Ended December 31, 2011
- Hollysys Automation Technologies Reports Unaudited Financial Results for the Fiscal Year 2012 Second Quarter Ended December 31, 2011
- Luna Innovations Reports First Quarter 2012 Financial Results
- PMC Reports First Quarter 2012 Results
- Euro Disney S.C.A. Reports Revenues for the First Quarter of Fiscal Year 2012
Natural Alternatives International, Inc. Announces Fiscal 2012 Q3 and YTD Results
-- Continued Increase in Net Sales and Income from Operations -- Posts 13th Consecutive Quarter of Profitability SAN MARCOS, Calif., May 14, 2012 /PRNewswire/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.1 million or $0.15 per diluted share on net sales of $17.4 million for the quarter ended March 31, 2012. These results included a full effective tax...continuedNAII validation Drugs Healthcare
Related News:
- United Natural Foods, Inc. Announces Second Quarter Fiscal 2012 Results
- Xilinx Announces Q3 Fiscal 2012 Results
- SIFCO Industries, Inc. Announces Fiscal 2012 First Quarter Financial Results
- Korn/Ferry International Announces Third Quarter Fiscal 2012 Results of Operations
- HNI Corporation Announces Improved Results For First Quarter Fiscal 2012
- F5 Networks Announces Results for Second Quarter of Fiscal 2012
- CVTech Group Inc. reports its financial results for the 1st quarter of fiscal 2012 and announces review of strategic alternatives